Johnson & Johnson is launching a new incubation model in Europe designed to identify and nurture early-stage companies actively pursuing research with the potential to transform human health. The initiative, a collaboration with Janssen Pharmaceutica NV, Inc. (Janssen), will be called Johnson & Johnson Innovation, JLINX (JLINX) will offer scientists and entrepreneurs access to venture funding, R&D expertise and state-of-the-art facilities. JLINX will have a particular focus on
Read More
- Skip to main content
- Skip to secondary menu
- Skip to primary sidebar
- Skip to secondary sidebar
- Skip to footer
Footer
